We report on a patient with phenylketonuria who developed disabling extrapyramidal features that were successfully controlled with L-dopa. We recommend that all such patients are given a trial with this drug.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.